survival after two and three years. Furthermore, this trial will evaluate patients' quality of life and ovarian function, and will explore the possibilities for disease monitoring in blood plasma (HPV ctDNA) and cervical scrapes (DNA hypermethylation).

**Results** Trial in progress: there are no available results at the time of submission.

**Conclusions** The CONTESSA/NEOCON-F trial is opened for accrual in the Netherlands, Canada, and the United States. Currently, 10% of the target accrual has been reached.